HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Dual-Target ADC Shows 15-Month Progression-Free Survival in Prostate Cancer: Tanya Dorff, MD

Dual-Target ADC Shows 15-Month Progression-Free Survival in Prostate Cancer: Tanya Dorff, MD

By AJMC · May 31, 2026 · via AJMC

This is an aggregated industry headline. Read the full story at AJMC →

Tags
theweekformat:headlineheadlineAJMC
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
The WeekFiercePharma ↗
ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
Although the first-in-class PD-1xVEGF bispecific didn't disappoint on its overall survival headline message, d…
Jun 1, 2026
ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
The WeekFierceBiotech ↗
ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
Although the first-in-class PD-1xVEGF bispecific didn't disappoint on its overall survival headline message, d…
Jun 1, 2026
AARP data show U.S. drug prices rise postlaunch as foreign prices fall
The WeekBriefing
AARP data show U.S. drug prices rise postlaunch as foreign prices fall
AARP found top U.S. brand-name drugs climbed 81% in list price since launch while prices abroad fell 13%, hint…
Jun 1, 2026